Literature DB >> 19050661

Confirming nasogastric tube position in the emergency department: pH testing is reliable.

Amanda Stock1, Heather Gilbertson, Franz E Babl.   

Abstract

OBJECTIVE: The aim of this study was to determine whether pH testing is an accurate method of confirming nasogastric tube (NGT) position in children with and without gastroenteritis in the emergency department.
METHODOLOGY: A prospective observational study of NGT insertions was conducted at a tertiary pediatric emergency department, during a 9-month period in 2006. We evaluated methods of NGT position confirmation, pH of nasogastric aspirates from patients with and without gastroenteritis, and adverse events.
RESULTS: A total of 404 patients were enrolled. For 393 patients (97.3%), NGT aspirates could be obtained to assess pH. Of these patients, 294 (74.8%) had a diagnosis of gastroenteritis and 99 (25.2%) did not. There was no difference in median pH between the patients with gastroenteritis (pH, 2; interquartile range, 2-4) and those without gastroenteritis (pH, 2; interquartile range, 2-4; P = 0.09). Overall, 341 patients (86.8%) had a pH of 4 or lower. The patients with gastroenteritis were more likely to have a pH of 4 or lower than the patients without gastroenteritis (P = 0.018). Tube position was confirmed by pH alone in 332 patients (84.5%). Nine (2.6%) of the 341 patients with a pH of 4 or lower also had radiography (7 for causes other than confirmation of NGT position) indicating correct placement of all NGTs. Fifty-two patients (13.2%) had a pH higher than 4, and 18 (34%) of these had the tube position confirmed by radiography, of which 3 had tubes misplaced in the distal esophagus. Irrespective of pH level, there were no respiratory placements clinically or by radiography. Overall, 22 patients (5.6% 95% CI 3.5%-8.3%) required more than 1 attempt for NGT insertion. There were 13 minor adverse events (3.3% 95% CI 1.8%-5.6%) and no major adverse events.
CONCLUSIONS: Testing of gastric pH is a reliable way of confirming NGT position when the pH is 4 or lower. When the pH is higher than 4, a radiograph may be necessary.

Entities:  

Mesh:

Year:  2008        PMID: 19050661     DOI: 10.1097/PEC.0b013e31818eb2d1

Source DB:  PubMed          Journal:  Pediatr Emerg Care        ISSN: 0749-5161            Impact factor:   1.454


  7 in total

Review 1.  Naso-enteric Tube Placement: A Review of Methods to Confirm Tip Location, Global Applicability and Requirements.

Authors:  S A Milsom; J A Sweeting; H Sheahan; E Haemmerle; J A Windsor
Journal:  World J Surg       Date:  2015-09       Impact factor: 3.352

2.  Role of Ultrasonography in Detecting the Localisation of the Nasoenteric Tube.

Authors:  Recai Dağlı; Hakan Bayır; Yeliz Dadalı; Turgut Tursem Tokmak; Zeynel Abidin Erbesler
Journal:  Turk J Anaesthesiol Reanim       Date:  2017-04-01

3.  Nasoduodenal tube placement: Are two views necessary to confirm position?

Authors:  Anh-Vu Ngo; Stephen Done; Randolph Otto; Seth Friedman; A Luana Stanescu
Journal:  Pediatr Radiol       Date:  2017-05-31

4.  Down the wrong road - a case report of inadvertent nasogastric tube insertion leading to lung laceration and important pearls to avoid complications.

Authors:  Syed Adnan Mohiuddin; Saad Al Kaabi; Tarik Butt; Rafie Yakoob; Maneesh Khanna
Journal:  Qatar Med J       Date:  2017-04-21

5.  Bedside ultrasonography for the confirmation of gastric tube placement in the neonate.

Authors:  Yunus Oktay Atalay; Ahmet Veysel Polat; Elif Ozyazici Ozkan; Leman Tomak; Canan Aygun; Joseph Drew Tobias
Journal:  Saudi J Anaesth       Date:  2019 Jan-Mar

6.  Validation of the RightSpot™ device for determination of gastric pH during nasogastric tube placement.

Authors:  Charles R Lambert; David Varlotta; Marjorie Posey; Jadie L Heberlein; Janice M Shirley
Journal:  Int J Emerg Med       Date:  2013-07-17

7.  A new strategy for enteral nutrition using a deflection flexible visual gastric tube: A randomized crossover manikin trial.

Authors:  Jie Li; Yan-Mei Feng; Dong Wan; Hui-Sheng Deng; Rui Guo
Journal:  Medicine (Baltimore)       Date:  2018-05       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.